InMed Pharmaceuticals Inc. 8-K

What Happened

• InMed Pharmaceuticals Inc. filed a Form 8-K on March 9, 2026 (Item 7.01) to announce its pharmaceutical development outlook for 2026.
• The company furnished a news release dated March 9, 2026 as Exhibit 99.1; the disclosure was made under Regulation FD (information furnished, not filed).

Key Details

• Filing date: March 9, 2026 (Form 8-K, Item 7.01 – Regulation FD Disclosure).
• Exhibit included: News release dated March 9, 2026 (Exhibit 99.1) was furnished with the 8-K.
• The 8-K indicates an outlook for the company’s pharmaceutical development programs in 2026 (read the attached press release for program-level specifics).

Why It Matters

• A company development outlook provides investors with management’s stated priorities and timelines for clinical and product development in the coming year, which can affect expectations for milestones, partnerships, or financing needs.
• Because the 8-K furnishes a press release rather than providing detailed program data in the filing itself, investors should review the attached Exhibit 99.1 and other company disclosures (e.g., press releases, investor presentations, SEC filings) for specific program details and milestone dates.